Header
Ihr Suchergebnis
Sie recherchieren derzeit unangemeldet.Melden Sie sich an (Login) um den vollen Funktionsumfang der Datenbank nutzen zu können.
Sie suchen in allen Bereichen nach dem Autor Ising J.
In der Rubrik Zeitschriften haben wir 1 Beitrag für Sie gefunden
-
MerkenStrengthening Clinical Control Through Analytics-Powered Drug Development
Rubrik: Fachthemen
(Treffer aus pharmind, Nr. 07, Seite 921 (2019))
Philipp M | Hodosi M | Ising J
Strengthening Clinical Control Through Analytics-Powered Drug Development / How Biopharma Can Redefine the Sponsor-CRO Relationship with Newfound Trust in Data · Philipp M, Hodosi M, Ising J · Accenture GmbH, Berlin
Today, it is expected that approximately 60 % of clinical development operations are externalized across the global biopharma industry, most commonly to one of a few large global Contract Research Organizations (CROs). In a fully outsourced drug development model, CROs thus can easily drive 60–80 % of a sponsor’s total R&D spend. Although these partnerships have proven to be very valuable, sponsors and CROs often have different perspectives. This is particularly glaring at the trial design stage, where CROs are credited with an information advantage, but also have incentives that may deviate from those of the sponsor. On the one hand, with ...
